At first Aclaris [Nasdaq: ACRS] didn't catch my eye. The phrase "concentrated hydrogen peroxide" sounded too simple to offer any sustainable competitive advantage.
However a favorable mention from the famous "Dr. KSS" who knows his biotechnology made me take a closer look. What I see is a fairly low-risk to treat a very common skin condition (Seborrheic Keratosis "SK") and a reasonable chance to expand into common warts and Alopecia Areata.
Their A-101 drug for SK is applied topically which is a major . . .